Population pharmacokinetics of total and unbound etoposide

被引:0
|
作者
Nguyen L. [1 ]
Chatelut E. [1 ,3 ]
Chevreau C. [1 ]
Tranchand B. [2 ]
Lochon I. [1 ]
Bachaud J.-M. [1 ]
Pujol A. [1 ]
Houin G. [3 ]
Bugat R. [3 ]
Canal P. [1 ]
机构
[1] Centre Claudius-Regaud
[2] Centre Léon-Bérard, Lyon
[3] Université Paul Sabatier
关键词
Etoposide; Population pharmacokinetics; Unbound fraction;
D O I
10.1007/s002800050718
中图分类号
学科分类号
摘要
A population pharmacokinetics study using the NONMEM program was undertaken to determine the effects of different covariates on the pharmacokinetic parameters of etoposide. A total of 1,044 plasma etoposide concentrations were determined by high-performance liquid chromatography (HPLC) in 100 patients (pts; 75 men and 25 women aged 25-85 years) treated for various tumor types with i.v. (57 pts) or oral (43 pts) etoposide. For 67 pts, etoposide plasma protein binding was determined by equilibrium dialysis; the unbound fraction ranged from 4% to 24%. A linear two-compartment model with first-order absorption (for oral dosing) accurately described the concentration versus time data. The central and peripheral volumes of distribution were significantly correlated with the body surface area [Vc (L) = 5.5 x BSA (m2) and Vp = 4.1 x BSA], but even after BSA had been taken into account, the interindividual variability of the two volumes remained high (34% and 57%, respectively). The clearance (CL) was not correlated with the following covariates: age, BSA, sex, height, and levels of serum bilirubin and liver enzymes. The final regression model for CL was CL (ml/min) = 49.8 x (1 - 0.009 x PRO) x WT/ Scr + 33.8 x (1 - 0.29 x META) x (1 - 0.012 x ALB), where ALB, PRO, WT, and Scr, respectively, were albuminemia, proteinemia (g/l), weight (kg), and serum creatinine (μM) and META = 1 if the patient had liver metastases (otherwise, META = 0). The interindividual variability in CL (mean value 30 ml/min) decreased only from 32% to 26% when these covariates were taken into account. The mean oral bioavailability was 66%, showing an interindividual variability of 37%. The plasma clearance of the unbound fraction was strongly and negatively correlated with Scr but was not dependent on either PRO or ALB. These data show that modifications in PRO levels do not directly affect plasma exposure to unbound etoposide. This analysis makes possible the rational consideration of modifications of covariates such as Scr in etoposide dosing. This population data base will constitute the prerequisite for adaptative control with feedback dosing for continuous oral administration of etoposide.
引用
收藏
页码:125 / 132
页数:7
相关论文
共 50 条
  • [1] Population pharmacokinetics of total and unbound etoposide
    Nguyen, L
    Chatelut, E
    Chevreau, C
    Tranchand, B
    Lochon, I
    Bachaud, JM
    Pujol, A
    Houin, G
    Bugat, R
    Canal, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 41 (02) : 125 - 132
  • [2] Population pharmacokinetics of total and unbound plasma cisplatin in adult patients
    Urien, S
    Lokiec, F
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (06) : 756 - 763
  • [3] Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients
    L. B. S. Aulin
    P. De Paepe
    E. Dhont
    A. de Jaeger
    J. Vande Walle
    W. Vandenberghe
    B. C. McWhinney
    J. P. J. Ungerer
    J. G. C. van Hasselt
    P. A. J. G. De Cock
    Clinical Pharmacokinetics, 2021, 60 : 353 - 363
  • [4] Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients
    Aulin, L. B. S.
    De Paepe, P.
    Dhont, E.
    de Jaeger, A.
    Vande Walle, J.
    Vandenberghe, W.
    McWhinney, B. C.
    Ungerer, J. P. J.
    van Hasselt, J. G. C.
    De Cock, P. A. J. G.
    CLINICAL PHARMACOKINETICS, 2021, 60 (03) : 353 - 363
  • [5] Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients
    Sime, Fekade B.
    Byrne, Catherine J.
    Parker, Suzanne
    Stuart, Janine
    Butler, Jenie
    Starr, Therese
    Pandey, Saurabh
    Wallis, Steven C.
    Lipman, Jeffrey
    Roberts, Jason A.
    CRITICAL CARE, 2019, 23 (1):
  • [6] Population pharmacokinetics of unbound ceftriaxone in a critically ill population
    Meenks, Sjoerd D.
    le Noble, Jos L. M. L.
    Foudraine, Norbert A.
    de Vries, Frank
    Neef , Kees
    Janssen, Paddy K. C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022, 60 (09) : 373 - 383
  • [7] Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy
    Byrne, Catherine J.
    Parton, Ted
    McWhinney, Brett
    Fennell, Jerome P.
    O'Byrne, Philomena
    Deasy, Evelyn
    Egan, Sean
    Enright, Helen
    Desmond, Ronan
    Ryder, Sheila A.
    D'Arcy, Deirdre M.
    McHugh, Johnny
    Roberts, Jason A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (04) : 995 - 1003
  • [8] Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients
    Fekade B. Sime
    Catherine J. Byrne
    Suzanne Parker
    Janine Stuart
    Jenie Butler
    Therese Starr
    Saurabh Pandey
    Steven C. Wallis
    Jeffrey Lipman
    Jason A. Roberts
    Critical Care, 23
  • [9] CHANGES IN THE CLEARANCE OF TOTAL AND UNBOUND ETOPOSIDE IN PATIENTS WITH LIVER DYSFUNCTION
    STEWART, CF
    ARBUCK, SG
    FLEMING, RA
    EVANS, WE
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (11) : 1874 - 1879
  • [10] Population pharmacokinetics and pharmacodynamics of oral etoposide
    Toffoli, G
    Corona, G
    Sorio, R
    Robieux, I
    Basso, B
    Colussi, AM
    Boiocchi, M
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (05) : 511 - 519